Midday Report: Cymabay (CBAY) Shares Climb for June 22

Equities Staff  |

Shares of Cymabay Therapeutics Inc (NASDAQ: CBAY) are up 11.65% Wednesday.

As of 11:50:48 est, Cymabay sits at $2.31 and has climbed $0.24 so far today.

Cymabay has moved 1.90% over the last 30 days and has moved YTD 39.05% based on the previous close.

The company expects its next earnings on 2022-08-11.

For technical charts, analysis, and more on Cymabay visit the company profile.

About Cymabay Therapeutics Inc

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. CymaBay is developing seladelpar, a potent, selective, orally active PPAR? agonist for patients with primary biliary cholangitis (PBC). Seladelpar has received an orphan designation from the US Food and Drug administration (FDA) and the European Medicine Agency (EMA). Seladelpar also received Breakthrough Therapy Designation from the FDA for early stage PBC and PRIority MEdicines status from the EMA. CymaBay is currently commencing a global, Phase 3 registration study of seladelpar for PBC. This study is a 52-week, placebo-controlled, randomized, phase 3 study to evaluate the safety and efficacy of seladelpar (RESPONSE) in patients with PBC.

To get more information on Cymabay Therapeutics Inc and to follow the company's latest updates, you can visit the company's profile page here: Cymabay Therapeutics Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade



Market Movers

Sponsored Financial Content